News|Videos|February 7, 2025
Strategies for Managing Cytopenias and Infection Prophylaxis with CAR-T Therapy
The conversation examines adverse events beyond CRS and neurotoxicities in CAR-T therapy, focusing on strategies for managing prolonged cytopenias, infection prophylaxis, and unique adverse events associated with ide-cel and cilta-cel.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Beyond CRS and neurotoxicities, are there other adverse events that require particular attention?
- How do you address prolonged cytopenias following CAR-T infusion?
- What is your approach to infection prophylaxis and management in these patients?
- Are there any distinct adverse events associated specifically with ide-cel or cilta-cel that clinicians should be aware of?
Advertisement
Related to this article
Coral Omene, MD, PhD, discusses the clinical impact of breast cancer disparities and how oncology nurses can support diverse trial recruitment.
An ONS review presented at EONS19 outlines 7 system-level employer strategies to curb oncology nurse burnout and improve retention.
A Columbia nurse scientist shares her takeaways from the 2026 ASCO Quality Care Symposium, from geriatric assessment to care across the age span.
A patient, a caregiver, nurses, an NP, and an oncologist discuss rash prevention, dose holds, cost, and trial eligibility with oral daraxonrasib.
In a 117-patient cohort, 35% waited over 60 days for neoadjuvant chemotherapy, most often because of added workup, second opinions or comorbidities.
Interviews with 15 young women with breast cancer show fertility preservation decisions unfold under time pressure and carry into survivorship.
Lisa Carter-Bawa, PhD, MPH, APRN, explains how nurses can counter lung cancer fatalism by pairing honesty with hope and using teach-back.
Interim AYA-NAV data show most navigation components reached young patients with cancer as designed, though full sessions lagged during treatment.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
2
Oncology Nurse Burnout: An Employer Blueprint From EONS19
3
Patients, Nurses Share What Daraxonrasib Means in Practice
4
How a Nurse's Question Changed Stem Cell Infusion Practice at UC Davis
5